Navigation Links
Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
Date:8/19/2007

d a two-stage min-max design in which if there were at least nine responses in the first 42 patients, the trial was to continue to the second stage. On January 25, 2007, the Company announced that there had been at least nine remissions in the first stage and that the trial would therefore continue. Eighty-five patients were enrolled in order to ensure that at least 77 would be eligible for the trial and included in the full analysis set. At least 22 responses in 77 patients are required to confirm the 35% target response rate with 95% confidence. If the full analysis set includes all 85 patients, then at least 24 responses are required for confirmation of the target response rate.

Dr. Dan DeAngelo, Assistant Professor at Harvard Medical School and the Dana Farber Cancer Institute and an investigator on the trial commented, "The treatment of elderly patients with poor-risk AML represents a significant unmet medical need in clinical oncology, and it is important that we find new effective treatment options. Agents such as Cloretazine(R) (VNP40101M) have the potential to address this need."

Dr. Gary Schiller, Professor of Medicine at the UCLA Geffen School of Medicine and an investigator on the trial added, "This was a very important study for older AML patients treated here at UCLA. As a single agent therapy administered over 30 to 60 minutes, Cloretazine(R) (VNP40101M) is clearly an active agent with the potential to play an important role in the treatment of this difficult population."

On August 8, 2007, the Company announced that certain sites on the trial would remain open and continue to accrue patients to an ECG sub-study. Recent FDA/ICH guidance recommends that an electrocardiographic evaluation (QT/QTc) study be included in the clinical development of all new drugs. Normally these studies are conducted in healthy subjects so that disease factors/co- morbidities do not confound the results. As Cloretazine(R) (VNP40101M) is a cytotoxic agent w
'/>"/>

SOURCE Vion Pharmaceuticals, Inc.

Copyright©2007 PR Newswire.

Page: 1 2 3 4

Related medicine technology :

1. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
2. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
5. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
6. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
7. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
8. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Keryx Biopharmaceuticals, Inc. Announces Positive Phase I and Phase II Data on KRX-0401 in Patients with Relapsed/Refractory Multiple Myeloma and Waldenstroms Macroglobulinemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)... , Feb. 27, 2015  Finesse expands office in ... Finesse Solutions announced the expansion of its operations in ... planned for mid-March and access for customers is expected ... A-563, and located adjacent to the current office, the ... Finesse automation engineering team and allow Finesse to bring on ...
(Date:2/26/2015)... RnRMarketResearch.com adds Corneal Ulcers ... to its store. This report p provides an ... The report "Corneal Ulcers - Pipeline Review, H2 2014" ... Corneal Ulcers. Corneal Ulcers are primarily result of ... infections & fungal infections. The symptoms of the ...
(Date:2/26/2015)... -- Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ), ... and t:flex™ Insulin Pumps, today announced the pricing of ... common stock at a price to the public of ... this offering are expected to be $56.3 million, after ... expenses payable by Tandem. All of the shares of ...
Breaking Medicine Technology:New Finesse Office in United Kingdom 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 2Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 3Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 4Corneal Ulcers Therapeutics Companies and Drugs Pipeline H2 2014 Review Research Report 5Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3
(Date:2/26/2015)... February 27, 2015 2015 Deep Market ... professional and in-depth study on the current state of ... focus on the Chinese situation. , Major companies included ... ZOUPING, Hualun, Jiangsu Yuanyang, ZHENGZHOU TONGLI, Hebei Tengye, ... Jain & Jain. , The report provides a basic ...
(Date:2/26/2015)... Danvers, MA (PRWEB) February 27, 2015 ... of enterprise mobility management services, and one of ... announced they have engaged business development firm The ... CLEAN 4.0, Wireless Analytics’ latest iteration of the ... suite of services. The Endurance Group, based ...
(Date:2/26/2015)... UAE Medical Insurance (UMI) is pleased to ... of Corporate Sales Director . Based in Dubai, Mr. Ward ... that he plans to leverage to help increase UMI’s reach ... health insurance industry in 1995, working for BUPA in the ... International - an agent of BUPA Global - in Dubai. ...
(Date:2/26/2015)... Abilene, Texas (PRWEB) February 27, 2015 Yisrayl ... Abilene, Texas has released a new letter that he says ... health and salvation. The letter starts by showing what the ... period has been given to mankind, which has a beginning ... to the living, to prove who will believe and walk ...
(Date:2/26/2015)... Guide to FDA Medical Device Regulations — ... a manufacturers needs to convince the FDA to accept ... implement UDI across a family of high-risk implantable devices, ... up-to-date, latest FDA regulations available. , ... is an FDAnews best-seller. , The 2015 Guide includes ...
Breaking Medicine News(10 mins):Health News:World Benzoyl Peroxide Market Forecast Report 2015-2020 Now at Available DeepResearchReports.com 2Health News:World Benzoyl Peroxide Market Forecast Report 2015-2020 Now at Available DeepResearchReports.com 3Health News:Wireless Analytics Engages The Endurance Group to Promote Upcoming CLEAN Platform™ 4.0 Launch 2Health News:Wireless Analytics Engages The Endurance Group to Promote Upcoming CLEAN Platform™ 4.0 Launch 3Health News:UAE Medical Insurance Hires New Head of Corporate Sales and Retention 2Health News:Yisrayl Hawkins Says There is Only One Place Shown in Scripture to Achieve Salvation and Shows Proof in New Letter 2Health News:FDAnews Bestseller Updated: Guide to FDA Medical Device Regulations — 2015 Edition 2
... from back pain, pelvic pressure, frequent urination or abnormal periods, ... growths found in the uterus and can range in size ... larger. Now, there’s an improvement to uterine fibroid embolization -- ... women. ,Hormone therapy can help shrink fibroids, and ...
... lung cancer before it’s in a more advanced stage is ... of a recent study.// While a CT scan can detect ... a cost-effective option. A new study conducted by researchers who ... for high-risk patients. ,The research was part of ...
... among men in the United States -- affecting nearly 200,000 ... new research shows there may be a way to prevent ... drug -- finasteride -- will make a difference in preventing ... for baldness. It works by stopping testosterone’s conversion to DHT ...
... to tobacco smoke. Infant exposure to environmental tobacco smoke ... asthma, and other respiratory conditions. ,A recent study ... of 314 infants living in smoking households. Participating infants ... from the University of Warwick, United Kingdom, found banning ...
... recent study shows only 7 percent of diabetics ... and blood vessel problems. // Researchers stressed continued ... disease including retinopathy, neuropathy, nephropathy, coronary heart disease, ... nearly 1,700 adults, ages 20 years or older, ...
... or water exercise, may improve strength and mobility in patients ... 100 patients with osteoarthritis who were older than age 50. ... three times a week in a swimming pool, the second ... at all. Both the water and gym programs focused on ...
Cached Medicine News:
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: